Squamous cell carcinoma of the oral region (OSCC) is one of the most common and highly aggressive malignancies worldwide, despite the fact that significant results have been achieved during the last decades in its detection, prevention and treatment. Although many efforts have been made to define the molecular signatures that identify the clinical outcome of oral cancers, OSCC still lacks reliable prognostic molecular markers. Scientific evidence indicates that transition from normal epithelium to pre-malignancy, and finally to oral carcinoma, depends on the accumulation of genetic and epigenetic alterations in a multistep process. Unlike genetic alterations, epigenetic changes are heritable and potentially reversible. The most common examples of such changes are DNA methylation, histone modification, and small non-coding RNAs. Although several epigenetic changes have been currently linked to OSCC initiation and progression, they have been only partially characterized. Over the last decade, it has been demonstrated that especially aberrant DNA methylation plays a critical role in oral cancer. The major goal of the present paper is to review the recent literature about the epigenetic modifications contribution in early and later phases of OSCC malignant transformation; in particular we point out the current evidence of epigenetic marks as novel markers for early diagnosis and prognosis as well as potential therapeutic targets in oral cancer.
References
[1]
Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin 2005, 55, 74–108.
[2]
Argiris, A.; Karamouzis, M.V.; Raben, D.; Ferris, R.L. Head and neck cancer. Lancet 2008, 371, 1695–1709.
[3]
Stewart, B.W.; Greim, H.; Shuker, D.; Kauppinen, T. Defence of IARC monographs. Lancet 2003, 361, doi:10.1016/S0140-6736(03).13003-6.
[4]
Mydlarz, W.K.; Hennessey, P.T.; Califano, J.A. Advances and perspectives in the molecular diagnosis of head and neck cancer. Expert Opin. Med. Diagn 2010, 4, 53–65.
[5]
Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J. Clin 2008, 58, 71–96.
[6]
Blot, W.J.; McLaughlin, J.K.; Winn, D.M.; Austin, D.F.; Greenberg, R.S.; Preston-Martin, S.; Bernstein, L.; Schoenberg, J.B.; Stemhagen, A.; Fraumeni, J.F., Jr. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988, 48, 3282–3287.
[7]
Gillison, M.L.; Koch, W.M.; Capone, R.B.; Spafford, M.; Westra, W.H.; Wu, L.; Zahurak, M.L.; Daniel, R.W.; Viglione, M.; Symer, D.E.; Shah, K.V.; Sidransky, D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst 2000, 92, 709–720.
[8]
Gillison, M.L.; D’Souza, G.; Westra, W.; Sugar, E.; Xiao, W.; Begum, S.; Viscidi, R. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J. Natl. Cancer Inst 2008, 100, 407–420.
[9]
Schlecht, N.F. Prognostic value of human papillomavirus in the survival of head and neck cancer patients: An overview of the evidence. Oncol. Rep 2005, 14, 1239–1247.
[10]
Chaturvedi, A.K.; Engels, E.A.; Anderson, W.F.; Gillison, M.L. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J. Clin. Oncol 2008, 26, 612–619.
[11]
Fakhry, C.; Westra, W.H.; Li, S.; Cmelak, A.; Ridge, J.A.; Pinto, H.; Forastiere, A.; Gillison, M.L. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst 2008, 100, 261–269.
[12]
Lingen, M.W.; Pinto, A.; Mendes, R.A.; Franchini, R.; Czerninski, R.; Tilakaratne, W.M.; Partridge, M.; Peterson, D.E.; Woo, S.B. Genetics/epigenetics of oral premalignancy: Current status and future research. Oral Dis 2011, 17, 7–22.
[13]
Saintigny, P.; Zhang, L.; Fan, Y.-H.; El-Naggar, A.K.; Papadimitrakopoulou, V.A.; Feng, L.; Lee, J.J.; Kim, E.S.; Hong, W.K.; Mao, L. Gene expression profiling predicts the development of oral cancer. Cancer Prev. Res 2011, 4, 218–229.
[14]
Kyrgidis, A.; Tzellos, T.G.; Triaridis, S. Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. J. Carcinog 2010, 9, doi:10.4103/1477-3163.62141..
[15]
Santos-Rosa, H.; Caldas, C. Chromatin modifier enzymes, the histone code and cancer. Eur. J. Cancer 2005, 41, 2381–2402.
[16]
Rountree, M.R.; Bachman, K.E.; Herman, J.G.; Baylin, S.B. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001, 20, 3156–3165.
[17]
Egger, G.; Liang, G.; Aparicio, A.; Jones, P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429, 457–463.
[18]
Feinberg, A.P.; Ohlsson, R.; Henikoff, S. The epigenetic progenitor origin of human cancer. Nat. Rev 2006, 7, 21–33.
[19]
Feinberg, A.P.; Tycko, B. The history of cancer epigenetics. Nat. Rev. Cancer 2004, 4, 143–153.
[20]
Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet 2002, 3, 415–428.
[21]
Board, R.E.; Knight, L.; Greystoke, A.; Blackhall, F.H.; Hughes, A.; Dive, C.; Ranson, M. DNA methylation in circulating tumour DNA as a biomarker for cancer. Biomark. Insights 2008, 2, 307–319.
[22]
Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev 2002, 16, 6–21.
[23]
Eden, A.; Gaudet, F.; Waghmare, A.; Jaenisch, R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300, doi:10.1126/science.1083557..
[24]
Bonazzi, V.F.; Irwin, D.; Hayward, N.K. Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. Genes Chromosom. Cancer 2009, 48, 10–21.
[25]
Feinberg, A.P.; Cui, H.; Ohlsson, R. DNA methylation and genomic imprinting: Insights from cancer into epigenetic mechanisms. Semin. Cancer Biol 2002, 12, 389–398.
[26]
Robertson, K.D. DNA methylation and human disease. Nat. Rev. Genet 2005, 6, 597–610.
[27]
Martinez, R.; Martin-Subero, J.I.; Rohde, V.; Kirsch, M.; Alaminos, M.; Fernandez, A.F.; Ropero, S.; Schackert, G.; Esteller, M. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 2009, 4, 255–264.
[28]
Herman, J.G. Hypermethylation of tumor suppressor genes in cancer. Semin. Cancer Biol 1999, 9, 359–367.
[29]
Baylin, S.B. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol 2005, 2, S4–S11.
[30]
Shaw, R. The epigenetics of oral cancer. Int. J. Oral. Maxillofac. Surg 2006, 35, 101–108.
[31]
Shaw, R.J.; Hall, G.L.; Woolgar, J.A.; Lowe, D.; Rogers, S.N.; Field, J.K.; Liloglou, T.; Risk, J.M. Quantitative methylation analysis of resection margins and lymph nodes in oral squamous cell carcinoma. Br. J. Oral. Maxillofac. Surg 2007, 45, 617–622.
[32]
Supi？, G.; Kozomara, R.; Brankovi？-Magi？, M.; Jovi？, N.; Magi？, Z. Gene hypermethylation in tumor tissue of advanced oral squamous cell carcinoma patients. Oral Oncol 2009, 45, 1051–1057.
[33]
Supic, G.; Jovic, N.; Kozomara, R.; Zeljic, K.; Magic, Z. Interaction between the MTHFR C677T polymorphism and alcohol—Impact on oral cancer risk and multiple DNA methylation of tumor-related genes. J. Dent. Res 2011, 90, 65–70.
[34]
Radhakrishnan, R.; Kabekkodu, S.; Satyamoorthy, K. DNA hypermethylation as an epigenetic mark for oral cancer diagnosis. J. Oral Pathol. Med 2011, 40, 665–679.
[35]
Fan, C.Y. Epigenetic alterations in head and neck cancer: Prevalence, clinical significance, and implications. Curr. Oncol. Rep 2004, 6, 152–161.
[36]
Shaw, R.J.; Hall, G.L.; Lowe, D.; Liloglou, T.; Field, J.K.; Sloan, P.; Risk, J.M. The role of pyrosequencing in head and neck cancer epigenetics: correlation of quantitative methylation data with gene expression. Arch. Otolaryngol. Head Neck Surg 2008, 134, 251–256.
[37]
Glazer, C.A.; Chang, S.S.; Ha, P.K.; Califano, J.A. Applying the molecular biology and epigenetics of head and neck cancer in everyday clinical practice. Oral Oncol 2009, 45, 440–446.
[38]
Bennett, K.L.; Hackanson, B.; Smith, L.T.; Morrison, C.D.; Lang, J.C.; Schuller, D.E.; Weber, F.; Eng, C.; Plass, C. Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res 2007, 67, 4657–4664.
[39]
de Freitas Cordeiro-Silva, M.; Oliveira, Z.F.; de Podestá, J.R.; Gouvea, S.A.; von Zeidler, S.V.; Louro, I.D. Methylation analysis of cancer-related genes in non-neoplastic cells from patients with oral squamous cell carcinoma. Mol. Biol. Rep 2011, 38, 5435–5441.
[40]
Calmon, M.F.; Rodrigues, R.V.; Kaneto, C.M.; Moura, R.P.; Silva, S.D.; Mota, L.D.; Pinheiro, D.G.; Torres, C.; de Carvalho, A.F.; Cury, P.M.; et al. Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia 2009, 11, 1329–1339.
[41]
Viswanathan, M.; Tsuchida, N.; Shanmugam, G. Promoter hypermethylation profile oftumorassociated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. Int. J. Cancer 2003, 105, 41–46.
[42]
Díez-Pérez, R.; Campo-Trapero, J.; Cano-Sánchez, J.; López-Durán, M.; Gonzalez-Moles, M.A.; Bascones-Ilundain, J.; Bascones-Martinez, A. Methylation in oral cancer and pre-cancerous lesions (Review). Oncol. Rep 2011, 25, 1203–1209.
[43]
Kulkarni, V.; Saranath, D. Concurrent hypermethylation of multiple regulatory genes in chewing tobacco associated oral squamous cell carcinomas and adjacent normal tissues. Oral. Oncol 2004, 40, 145–153.
[44]
Mancuso, M.; Matassa, D.S.; Conte, M.; Colella, G.; Rana, G.; Fucci, L.; Piscopo, M. H3K4 histone methylation in oral squamous cell carcinoma. Acta Biochim. Pol 2009, 56, 405–410.
[45]
Lee, E.S.; Issa, J.P.; Roberts, D.B.; Williams, M.D.; Weber, R.S.; Kies, M.S.; El-Naggar, A.K. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: Comparison with methylation-specific PCR technique and clinical significance. Clin. Cancer Res 2008, 14, 2664–2672.
[46]
Kozaki, K.; Imoto, I.; Mogi, S.; Omura, K.; Inazawa, J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008, 68, 2094–2105.
[47]
Kurasawa, Y.; Shiiba, M.; Nakamura, M.; Fushimi, K.; Ishigami, T.; Bukawa, H.; Yokoe, H.; Uzawa, K.; Tanzawa, H. PTEN expression and methylation status in oral squamous cell carcinoma. Oncol. Rep 2008, 19, 1429–1434.
[48]
Squarize, C.H.; Castilho, R.M.; Santos Pinto, D., Jr. Immunohistochemical evidence of PTEN in oral squamous cell carcinoma and its correlation with the histological malignancy grading system. J. Oral Pathol. Med. 2002, 31, 379–384.
[49]
Shin, K.H.; Kim, J.M.; Rho, K.S.; Park, K.H.; Oh, J.E.; Min, B.M. Inactivation of the PTEN gene by mutation, exonic deletion, and loss of transcript in human oral squamous cell carcinomas. Int. J. Oncol 2002, 21, 997–1001.
[50]
Lee, J.I.; Soria, J.C.; Hassan, K.A.; El-Naggar, A.K.; Tang, X.; Liu, D.D.; Hong, W.K.; Mao, L. Loss of PTEN expression as a prognostic marker for tongue cancer. Arch. Otolaryngol. Head Neck Surg 2001, 127, 1441–1445.
[51]
Huang, K.H.; Huang, S.F.; Chen, I.H.; Liao, C.T.; Wang, M.; Hsieh, L.L. Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. Clin. Cancer Res 2009, 15, 4174–4180.
Sogabe, Y.; Suzuki, H.; Toyota, M.; Ogi, K.; Imai, T.; Nojima, M.; Sasaki, Y.; Hiratsuka, H.; Tokino, T. Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma. Int. J. Oncol 2008, 32, 1253–1261.
[54]
Huang, M.J.; Yeh, K.T.; Shih, H.C.; Wang, Y.F.; Lin, T.H.; Chang, J.Y.; Shih, M.C.; Chang, J.G. The correlation between CpG methylation and protein expression of P16 in oral squamous cell carcinomas. Int. J. Mol. Med 2002, 10, 551–554.
[55]
Nakahara, Y.; Shintani, S.; Mihara, M.; Ueyama, Y.; Matsumura, T. High frequency of homozygous deletion and methylation of p16(INK4A) gene in oral squamous cell carcinomas. Cancer Lett 2001, 163, 221–228.
[56]
Ogi, K.; Toyota, M.; Ohe-Toyota, M.; Tanaka, N.; Noguchi, M.; Sonoda, T.; Kohama, G.; Tokino, T. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin. Cancer Res 2002, 8, 3164–3171.
[57]
Maruya, S.; Issa, J.P.; Weber, R.S.; Rosenthal, D.I.; Haviland, J.C.; Lotan, R.; El-Naggar, A.K. Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: Incidence and potential implications. Clin. Cancer Res 2004, 10, 3825–3830.
[58]
Kato, K.; Hara, A.; Kuno, T.; Mori, H.; Yamashita, T.; Toida, M.; Shibata, T. Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. J. Cancer Res. Clin. Oncol 2006, 132, 735–743.
[59]
Kresty, L.A.; Mallery, S.R.; Knobloch, T.J.; Song, H.; Lloyd, M.; Casto, B.C.; Weghorst, C.M. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia. Cancer Res 2002, 62, 5295–5300.
[60]
Takeshima, M.; Saitoh, M.; Kusano, K.; Nagayasu, H.; Kurashige, Y.; Malsantha, M.; Arakawa, T.; Takuma, T.; Chiba, I.; Kaku, T.; et al. High frequency of hypermethylation of p14, p15 and p16 in oral pre-cancerous lesions associated with betel-quid chewing in Sri Lanka. J. Oral Pathol. Med 2008, 37, 475–479.
[61]
Saito, Y.; Takazawa, H.; Uzawa, K.; Tanzawa, H.; Sato, K. Reduced expression of E-cadherin in oral squamous cell carcinoma: Relationship with DNA methylation of 5′ CpG island. Int. J. Oncol 1998, 12, 293–298.
[62]
Nakayama, S.; Sasaki, A.; Mese, H.; Alcalde, R.E.; Tsuji, T.; Matsumura, T. The E-cadherin gene is silenced by CpG methylation in human oral squamous cell carcinomas. Int. J. Cancer 2001, 93, 667–673.
[63]
Chang, H.W.; Chow, V.; Lam, K.Y.; Wei, W.I.; Yuen, A. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer 2002, 94, 386–392.
[64]
Hasegawa, M.; Nelson, H.H.; Peters, E.; Ringstrom, E.; Posner, M.; Kelsey, K.T. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 2002, 21, 4231–4236.
[65]
Viet, C.T.; Jordan, R.C.; Schmidt, B.L. DNA promoter hypermethylation in saliva for the early diagnosis of oral cancer. J. Calif. Dent. Assoc 2007, 35, 844–849.
[66]
Vered, M.; Allon, I.; Buchner, A.; Dayan, D. E-cadherin in oral SCC: An analysis of the confusing literature and new insights related to its immunohistochemical expression. Histol. Histopathol 2012, 27, 141–150.
[67]
Di Domenico, M.; Pierantoni, G.M.; Feola, A.; Esposito, F.; Laino, L.; de Rosa, A.; Rullo, R.; Mazzotta, M.; Martano, M.; Sanguedolce, F.; et al. Prognostic significance of N-cadherin expression in oral squamous cell carcinoma. Anticancer Res 2011, 12, 4211–4218.
[68]
Renner, O.; Blanco-Aparicio, C.; Carnero, A. Genetic modelling of the PTEN/AKT pathway in cancer research. Clin. Transl. Oncol 2008, 10, 618–627.
[69]
Zhu, Y.; Wloch, A.; Wu, Q.; Peters, C.; Pagenstecher, A.; Bertalanffy, H.; Sure, U. Involvement of PTEN promoter methylation in cerebral cavernous malformations. Stroke 2009, 40, 820–826.
[70]
Salvesen, H.B.; MacDonald, N.; Ryan, A.; Jacobs, I.J.; Lynch, E.D.; Akslen, L.A.; Das, S. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int. J. Cancer 2001, 91, 22–26.
[71]
Kang, Y.H.; Lee, H.S.; Kim, W.H. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab. Invest 2002, 82, 285–291.
[72]
Soria, J.C.; Lee, H.Y.; Lee, J.I.; Wang, L.; Issa, J.P.; Kemp, B.L.; Liu, D.D.; Kurie, J.M.; Mao, L.; Khuri, F.R. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer Res 2002, 8, 1178–1184.
[73]
Yang, H.J.; Liu, V.W.; Wang, Y.; Tsang, P.C.; Ngan, H.Y. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 2006, 6, doi:10.1186/1471-2407-6-212..
[74]
Chen, Q.; Samaranayake, L.P.; Zhou, H.; Xiao, L. Homozygous deletion of the PTEN tumor-suppressor gene is not a feature in oral squamous cell carcinoma. Oral Oncol 2000, 36, 95–99.
[75]
Mavros, A.; Hahn, M.; Wieland, I.; Koy, S.; Koufaki, O.N.; Strelocke, K.; Koch, R.; Haroske, G.; Schackert, H.K.; Eckelt, U. Infrequent genetic alterations of the tumor suppressor gene PTEN/MMAC1 in squamous cell carcinoma of the oral cavity. J. Oral Pathol. Med 2002, 31, 270–276.
[76]
Koch, R.; Haroske, G.; Schackert, H.K.; Eckelt, U. Infrequent genetic alterations of the tumor suppressor gene PTEN/MMAC1 in squamous cell carcinoma of the oral cavity. J. Oral Pathol. Med 2002, 31, 270–276.
Boyle, J.O.; Hakim, J.; Koch, W.; van der Riet, P.; Hruban, R.H.; Roa, R.A.; Correo, R.; Eby, Y.J.; Ruppert, J.M.; Sidransky, D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993, 53, 4477–4480.
[79]
Caamano, J.; Zhang, S.Y.; Rosvold, E.A.; Bauer, B.; Klein-Szanto, A.J. p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am. J. Pathol 1993, 142, 1131–1139.
[80]
Baral, R.; Patnaik, S.; Das, B.R. Co-overexpression of p53 and c-myc proteins linked with advanced stages of betel- and tobacco-related oral squamous cell carcinomas from eastern India. Eur. J. Oral Sci. 1998, 106, 907–913.
[81]
Ha, P.K.; Califano, J.A. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 2006, 7, 77–82.
[82]
Sanchez-Cespedes, M.; Esteller, M.; Wu, L.; Nawroz-Danish, H.; Yoo, G.H.; Koch, W.M.; Jen, J.; Herman, J.G.; Sidransky, D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000, 60, 892–895.
[83]
Rosas, S.L.; Koch, W.; da Costa Carvalho, M.G.; Wu, L.; Califano, J.; Westra, W.; Jen, J.; Sidransky, D. Promoter hypermethylation patterns of p16, O6-methylguanine-DNAmethyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001, 61, 939–942.
[84]
Roth, M.J.; Abnet, C.C.; Hu, N.; Wang, Q.H.; Wie, W.Q.; Green, L.; D’Alelio, M.; Qiao, Y.L.; Dawsey, S.M.; Taylor, P.R.; Woodson, K. p16, MGMT, RARbeta2, CLDN3, CRBP and MT1G gene methylation in esophageal squamous cell carcinoma and its precursor lesions. Oncol. Rep 2006, 15, 1591–1597.
[85]
Sawhney, M.; Rohatgi, N.; Kaur, J.; Gupta, S.D.; Deo, S.V.; Shukla, N.K.; Ralhan, R. MGMT expression in oral precancerous and cancerous lesions: Correlation with progression, nodal metastasis and poor prognosis. Oral Oncol 2007, 43, 515–522.
[86]
Youssef, E.M.; Lotan, D.; Issa, J.; Wakasa, K.; Fan, Y.H.; Mao, L.; Hassan, K.; Feng, L.; Lee, J.J.; Lippman, S.M.; et al. Hypermethylation of the retinoic acid receptor-β(2) gene in head and neck carcinogenesis. Clin. Cancer Res 2004, 10, 1733–1742.
[87]
Imai, T.; Toyota, M.; Suzuki, H.; Akino, K.; Ogi, K.; Sogabe, Y.; Kashima, L.; Maruyama, R.; Nojima, M.; Mita, H.; et al. Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma. Cancer Sci 2008, 99, 958–966.
[88]
Sigalotti, L.; Covre, A.; Fratta, E.; Parisi, G.; Colizzi, F.; Rizzo, A.; Danielli, R.; Nicolay, H.J.; Coral, S.; Maio, M. Epigenetics of human cutaneous melanoma: Setting the 66 research on Melanoma: A glimpse into current directions and future trends stage for new therapeutic strategies. J. Transl. Med 2010, 8, 56.
[89]
Guil, S.; Esteller, M. DNA methylomes, histone codes and miRNAs: Tying it all together. Int. J. Biochem. Cell Biol 2009, 41, 87–95.
[90]
Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857–866.
[91]
Sood, P.; Krek, A.; Zavolan, M.; Macino, G.; Rajewsky, N. Cell-type-specific signatures of microRNAs on target mRNA expression. Proc. Natl. Acad. Sci. USA 2006, 103, 2746–2751.
[92]
Lujambio, A.; Ropero, S.; Ballestar, E.; Fraga, M.F.; Cerrato, C.; Setién, F.; Casado, S.; Suarez-Gauthier, A.; Sanchez-Cespedes, M.; Git, A.; et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007, 67, 1424–1429.
[93]
Saito, Y.; Liang, G.; Egger, G.; Friedman, J.M.; Chuang, J.C.; Coetzee, G.A.; Jones, P.A. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9, 435–443.
[94]
Cervigne, N.K.; Reis, P.P.; Machado, J.; Sadikovic, B.; Bradley, G.; Galloni, N.N.; Pintilie, M.; Jurisica, I.; Perez-Ordonez, B.; Gilbert, R.; et al. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum. Mol. Genet 2009, 18, 4818–4829.
[95]
Wong, T.S.; Liu, X.B.; Chung-Wai Ho, A.; Po-Wing Yuen, A.; Wai-Man Ng, R.; Ignace Wei, W. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int. J. Cancer 2008, 123, 251–257.
[96]
Olive, V.; Jiang, I.; He, L. mir-17–92, a cluster of miRNAs in the midst of the cancer network. Int. J. Biochem. Cell Biol 2010, 42, 1348–1354.
[97]
Jevnaker, A.M.; Khuu, C.; Kj？le, E.; Bryne, M.; Osmundsen, H. Expression of members of the miRNA17–92 cluster during development and in carcinogenesis. J. Cell. Physiol 2011, 226, 2257–2266.
Wu, B.H.; Xiong, X.P.; Jia, J.; Zhang, W.F. MicroRNAs: New actors in the oral cancer scene. Oral Oncol 2011, 47, 314–319.
[100]
Gorenchtein, M.; Poh, C.F.; Saini, R.; Garnis, C. MicroRNAs in an oral cancer context—From basic biology to clinical utility. J. Dent. Res 2011, doi:10.1177/0022034511431261..
Strahl, B.D.; Allis, C.D. The language of covalent histone modifications. Nature 2000, 403, 41–45.
[103]
Ramirez-Parra, E.; Gutierrez, C. The many faces of chromatin assembly factor 1. Trends Plant Sci 2007, 12, 570–576.
[104]
Ridgway, P.; Almouzni, G. CAF-1 and the inheritance of chromatin states: At the crossroads of DNA replication and repair. J. Cell Sci 2000, 113, 2647–2658.
[105]
Das, C.; Lucia, M.S.; Hansen, K.C.; Tyler, J.K. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 2009, 459, 113–117.
[106]
Li, Q.; Huang, Y.; Xiao, N.; Murray, V.; Chen, J.; Wang, J. Real time investigation of protein folding, structure, and dynamics in living cells. Methods Cell Biol 2008, 90, 287–325.
[107]
Chen, C.C.; Tyler, J. Chromatin reassembly signals the end of DNA repair. Cell Cycle 2008, 7, 3792–3797.
[108]
Kadyrova, L.Y.; Blanko, E.R.; Kadyrov, F.A. CAF-I-dependent control of degradation of the discontinuous strands during mismatch repair. Proc. Natl. Acad. Sci. USA 2011, 108, 2753–2758.
[109]
Kim, J.A.; Haber, J.E. Chromatin assembly factors Asf1 and CAF-1 have overlapping roles in deactivating the DNA damage checkpoint when DNA repair is complete. Proc. Natl. Acad. Sci. USA 2009, 106, 1151–1156.
[110]
Henikoff, S. Versatile assembler. Nature 2003, 423, 814– 817.
[111]
Polo, S.E.; Theocharis, S.E.; Klijanienko, J.; Savignoni, A.; Asselain, B.; Vielh, P.; Almouzni, G. Chromatin Assembly Factor-1, a marker of clinical value to distinguish quiescent from proliferating cells. Cancer Res 2004, 64, 2371–2381.
[112]
Ye, X.; Franco, A.A.; Santos, H.; Nelson, D.M.; Kaufmann, P.D.; Adams, P.D. Defective S phase chromatin assembly causes DNA damage, activation of the S phase checkpoint, and S phase arrest. Mol. Cell 2003, 11, 341–351.
[113]
Gaillard, P.H.; Martini, E.M.; Kaufman, P.D.; Stillman, B.; Moustacchi, E.; Almouzni, G. Chromatin assembly coupled to DNA repair: A new role for chromatin assembly factor I. Cell 1996, 86, 887–896.
[114]
Techenio, T.; Casella, J.F.; Heidmann, T. A truncated form of human CAF-1 p150 subunits impairs the maintenance of transcriptional gene silencing in mammalian cells. Mol. Cell. Biol 2001, 21, 953–961.
[115]
Staibano, S.; Mascolo, M.; Mancini, F.P.; Kisslinger, A.; Salvatore, G.; Di Benedetto, M.; Chieffi, P.; Altieri, V.; Prezioso, D.; Ilardi, G.; et al. Overexpression of chromatin assembly factor-1 (CAF-1) p60 is predictive of adverse behaviour of prostatic cancer. Histopathology 2009, 54, 580–589.
[116]
Mascolo, M.; Vecchione, M.L.; Ilardi, G.; Scalvenzi, M.; Molea, G.; Di Benedetto, M.; Nugnes, L.; Siano, M.; de Rosa, G.; Staibano, S. Overexpression of Chromatin Assembly Factor-1/p60 helps to predict the prognosis of melanoma patients. BMC Cancer 2010, 24, doi:10.1186/1471-2407-10-63..
[117]
Staibano, S.; Mascolo, M.; Rocco, A.; Lo Muzio, L.; Ilardi, G.; Siano, M.; Pannone, G.; Vecchione, M.L.; Nugnes, L.; Califano, L.; et al. The proliferation marker Chromatin Assembly Factor-1 is of clinical value in predicting the biological behaviour of salivary gland tumours. Oncol. Rep 2011, 25, 13–22.
[118]
Staibano, S.; Mignogna, C.; Lo Muzio, L.; Mascolo, M.; Salvatore, G.; Di Benedetto, M.; Califano, L.; Rubini, C.; de Rosa, G. Chromatin assembly factor-1 (CAF-1)-mediated regulation of cell proliferation and DNA repair: A link with the biological behaviour of squamous cell carcinoma of the tongue? Histopathology 2007, 50, 911–919.
[119]
Polo, S.E.; Theocharis, S.E.; Grandin, L.; Gambotti, L.; Antoni, G.; Savignoni, A.; Asselain, B.; Patsouris, E.; Almouzni, G. Clinical significance and prognostic value of chromatin assembly factor-1 overexpression in human solid tumours. Histopathology 2010, 57, 716–724.
[120]
Sakuma, T.; Uzawa, K.; Onda, T.; Shiiba, M.; Yokoe, H.; Shibahara, T.; Tanzawa, H. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int. J. Oncol 2006, 29, 117–124.
[121]
Sato, T.; Suzuki, M.; Sato, Y.; Echigo, S.; Rikiishi, H. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int. J. Oncol 2006, 28, 1233–1241.
[122]
Rikiishi, H.; Shinohara, F.; Sato, T.; Sato, Y.; Suzuki, M.; Echigo, S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int. J. Oncol 2007, 30, 1181–1188.
Chung, Y.L.; Lee, M.Y.; Pui, N.N. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: Prevention of radiationinduced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis 2009, 30, 1387–1397.
[125]
Shen, J.; Huang, C.; Jiang, L.; Gao, F.; Wang, Z.; Zhang, Y.; Bay, J.; Zhou, H.; Chen, Q. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem. Pharmacol 2007, 73, 1901–1909.
[126]
Murakami, J.; Asaumi, J.; Maki, Y.; Tsujigiwa, H.; Kuroda, M.; Nagai, N.; Yanagi, Y.; Inoue, T.; Kawasaki, S.; Tanaka, N.; et al. Effects of demethylating agent 5-aza-2(0)-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines. Oral Oncol 2004, 40, 597–603.
[127]
Murakami, J.; Asaumi, J.; Kawai, N.; Tsujigiwa, H.; Yanagi, Y.; Nagatsuka, H.; Inoue, T.; Kokeguchi, S.; Kawasaki, S.; Kuroda, M.; et al. Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer. Cancer Chemother. Pharmacol 2005, 56, 22–28.
[128]
D’Souza, G.; Kreimer, A.R.; Viscidi, R.; Pawlita, M.; Fakhry, C.; Koch, W.M.; Westra, W.H.; Gillison, M.L. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med 2007, 356, 1944–1956.
[129]
Adelstein, D.J.; Rodriguez, C.P. Human papillomavirus: Changing paradigms in oropharyngeal cancer. Curr. Oncol. Rep 2010, 12, 115–120.
[130]
Stock, M.L.; Peterson, L.M.; Houlihan, A.E.; Walsh, L.A. Influence of oral sex and oral cancer information on young adults’ oral sexual-risk cognitions and likelihood of hpv vaccination. J. Sex Res 2012, doi:10.1111/j.1365-263X.2011.01219.x..
[131]
Murugan, A.K.; Munirajan, A.K.; Tsuchida, N. Ras oncogenes in oral cancer: The past 20 years. Oral Oncol 2012, doi:10.1016/j.oraloncology.2011.12.006..
[132]
Sanders, A.; Slade, G.; Patton, L. National prevalence of oral HPV infection and related risk factors in the US adult population. Oral Dis 2011, doi:10.1111/j.1601-0825.2011.01892.x..
[133]
Miller, C.S.; Johnstone, B.M. Human papillomavirus as a risk factor for oral squamous cell carcinoma: A meta- analysis, 1982–1997. Oral Surg. Oral Med. Oral. Pathol. Oral Radiol. Endod 2001, 91, 622–635.
[134]
Syrjanen, S.; Syrjanen, K. HPV Infections of the Oral Mucosa. In Papillomavirus Infections in Human Pathology; Syrjanen, K., Syrjanen, S., Eds.; John Wiley & Sons: New York, NY, USA, 2000; Volume Chapter 17, pp. 379–412.
[135]
Syrj？nen, S.; Lodi, G.; von Bültzingsl？wen, I.; Aliko, A.; Arduino, P.; Campisi, G.; Challacombe, S.; Ficarra, G.; Flaitz, C.; Zhou, H.M.; et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: A systematic review. Oral Dis 2011, 17, 58–72.
[136]
Termine, N.; Panzarella, V.; Falaschini, S.; Russo, A.; Matranga, D.; Lo Muzio, L.; Campisi, G. HPV in oral squamous cell carcinoma vs. head and neck squamous cell carcinoma biopsies: A meta-analysis (1988–2007). Ann. Oncol 2008, 10, 1681–1690.
[137]
Kreimer, A.R.; Clifford, G.M.; Boyle, P.; Franceschi, S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol. Biomark. Prev 2005, 14, 467–475.
[138]
Smith, E.M.; Ritchie, J.M.; Yankowitz, J.; Swarnavel, S.; Wang, D.; Haugen, T.H.; Turek, L.P. Human papillomavirus prevalence and types in newborns and parents: Concordance and modes of transmission. Sex Transm. Dis 2004, 1, 57–62.
[139]
Dayyani, F.; Etzel, C.J.; Liu, M.; Ho, C.H.; Lippman, S.M.; Tsao, A.S. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010, 2, doi:10.1186/1758-3284-2-15..
[140]
Zhao, D.; Xu, Q.G.; Chen, X.M.; Fan, M.W. Human papillomavirus as an independent predictor in oral squamous cell cancer. Int. J. Oral Sci 2009, 1, 119–125.
[141]
Shi, W.; Kato, H.; Perez-Ordonez, B.; Pintilie, M.; Huang, S.; Hui, A.; O’Sullivan, B.; Waldron, J.; Cummings, B.; Kim, J.; et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J. Clin. Oncol 2009, 27, 6213–6221.
[142]
Wiest, T.; Schwarz, E.; Enders, C.; Flechtenmacher, C.; Bosch, F.X. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002, 21, 1510–1517.
[143]
Boyer, S.N.; Wazer, D.E.; Band, V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996, 56, 4620–4624.
[144]
Snow, A.; Laudadio, J. Human papillomavirus detection in head and neck squamous cell carcinomas. Adv. Anat. Pathol 2010, 17, 394–403.
[145]
Smeets, S.J.; Hesselink, A.T.; Speel, E.J.; Haesevoets, A.; Snijders, P.J.; Pawlita, M.; Meijer, C.J.; Braakhuis, B.J.; Leemans, C.R.; Brakenhoff, R.H. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int. J. Cancer 2007, 121, 2465–2472.
[146]
Patel, D.; Huang, S.M.; Baglia, L.A.; McCance, D.J. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 1999, 18, 5061–5072.
[147]
Longworth, M.S.; Laimins, L.A. The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. J. Virol 2004, 78, 3533–3541.
[148]
Lin, T.S.; Lee, H.; Chen, R.A.; Ho, M.L.; Lin, C.Y.; Chen, Y.H.; Tsai, Y.Y.; Chou, M.C.; Cheng, Y.W. An association of DNMT3b protein expression with P16INK4a promoter hypermethylation in non-smoking female lung cancer with human papillomavirus infection. Cancer Lett 2005, 226, 77–84.
[149]
Burgers, W.A.; Blanchon, L.; Pradhan, S.; de Launoit, Y.; Kouzarides, T.; Fuks, F. Viral oncoproteins target the DNA methyltransferases. Oncogene 2007, 26, 1650–1655.
[150]
Gore, D.S. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat. Clin. Pract. Oncol 2005, 2, S30–S35.
[151]
Quintás-Cardama, A.; Santos, F.P.; Garcia-Manero, G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011, 25, 226–235.
[152]
Momparler, R.L.; Ayoub, J. Potential of 5-aza-2′-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 2001, 34, S111–S115.
[153]
Coombes, M.M.; Briggs, K.L.; Bone, J.R.; Clayman, G.L.; El-Naggar, A.K.; Dent, S.Y. Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation. Oncogene 2003, 22, 8902–8911.
[154]
ClinicalTrials Home Page, Available online: http://www.clinicaltrials.gov , accessed on 21 February 2012.
[155]
Balch, C.; Yan, P.; Craft, T.; Young, S.; Skalnik, D.G.; Huang, T.H.; Nephew, K.P. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol. Cancer Ther 2005, 4, 1505–1514.
[156]
Suzuki, M.; Shinohara, F.; Nishimura, K.; Echigo, S.; Rikiishi, H. Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma. Int. J. Oncol 2007, 31, 1449–1456.
